Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis

Gastrointestinal Endoscopy

Volumn 65, Issue 4, 2007, Pages 624-632

  Andriulli, Angelo ^a   Leandro, Gioacchino ^a   Federici, Telemaco ^a   Ippolito, Antonio ^a   Forlano, Rosario ^a   Iacobellis, Angelo ^a   Annese, Vito ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GABEXATE MESILATE; PLACEBO; SOMATOSTATIN;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; PAIN ASSESSMENT; PANCREATITIS; PATIENT CARE; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; RISK REDUCTION;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GABEXATE; HORMONES; HUMANS; HYPERAMYLASEMIA; PANCREATITIS; SERINE PROTEINASE INHIBITORS; SOMATOSTATIN;

EID: 33947420914     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2006.10.030     Document Type: Article

References (43)

1. Freeman M.L., Nelson D.B., Sherman S., et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 335 (1996) 909-918
2. Loperfido S., Angelini G., Benedetti G., et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 48 (1998) 1-10
3. Masci E., Toti G., Mariani A., et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 96 (2001) 417-423
4. Vandervoort J., Soetikno M., Tham T.C.K., et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 56 (2002) 652-656
5. Andriulli A., Leandro G., Niro G., et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 51 (2000) 1-7
6. Andriulli A., Clemente R., Solmi L., et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 56 (2002) 488-495
7. Freeman M.L., and Guda N.M. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59 (2004) 845-863
8. Saluja A.K., and Steer M.L. Pathophysiology of pancreatitis: role of cytokines and other mediators of inflammation. Digestion 60 Suppl 1 (1999) 27-33
9. Andriulli A., Solmi L., Loperfido S., et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesilate. Clin Gastroenterol Hepatol 2 (2004) 713-716
10. Xiong G.S., Wu S.M., Zhang X.M., et al. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 39 (2006) 85-90
11. Poon R.T., Yeung C., Liu C.L., et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut 52 (2003) 1768-1773
12. Arvanitidis D., Anagnostopoulos G.K., Giannopoulos D., et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 19 (2004) 278-282
13. Masci E., Cavallini G., Mariani A., et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 35 (2003) 830-834
14. Vila J.J., Jimenez F.J., Prieto G., et al. Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study. Gastroenterol Hepatol 29 (2006) 231-236
15. Andriulli A., Caruso N., Quitadamo M., et al. Antisecretory vs antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP 4 (2003) 9001-9008
16. Benvenuti S., Zancanella L., Piazzi L., et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesilate: a randomized placebo-controlled multicenter study. [abstract]. Dig Liv Dis 38 (2006) S15
17. Manes G., Lombardi G., Pieramico O., et al. The impact of timing on the efficacy of Foy in the prevention of acute pancreatitis: a randomised study comparing prior vs after-ERCP administration. [abstract]. Dig Liv Dis 38 (2006) 23
18. Stordilis P.G., Voumvouraki A., Vardas E., et al. Somatostatin can be efficient for the prevention of the post-ERCP pancreatitis?. [abstract]. Endoscopy 37 I Suppl (2005) A279
19. Borsch G., Bergbauer M., Nebel W., et al. Der einfluβ von somatostatin auf die amylasespiegel und pankreatitistrate nach ERCP. [German]. Med Welt 35 (1984) 109-112
20. Cicero G.F., Lauger R., Sahel J., et al. Effect of somatostatin on clinical, biochemical and morphological changes following ERCP. Ital J Gastroenterol 17 (1985) 265-268
21. Tyden G., Nyberg B., Sonnenfeld T., et al. Effect of somatostatin on hyperamylasemia following endoscopic pancreatography. Acta Chir Scand 530 (1986) 43-45
22. Flati G., Porowska B., Negro P., et al. Efecto de la somatostatina sobre las secuelas de la colangiopancreatografia retrograda endoscopica. Rev Esp Enf Ap Digest 74 (1988) 17-19
23. Deschner K., Kalloo A., Collen M., et al. Somatostatin: an evaluation of its utility as adjunctive medication for ERCP. [abstract]. Gastrointest Endosc 35 (1989) A149
24. Guelrud M., Mendoza S., Viera L., et al. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 36 (1990) 44-47
25. Bordas M., Toledo V., Mondalo F., et al. Prevention of pancreatic reaction by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy. Hormone Res 29 (1988) 106-108
26. Bordas J.M., Toledo-Pimentel V., Llach J., et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 47 (1998) 230-234
27. Testoni P.A., Masci E., Bagnolo F., et al. Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastroenterol 20 (1988) 70-73
28. Saari A., Kivilaakso E., and Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography: an experimental and clinical study. Surg Res Comm 2 (1988) 271-278
29. Persson B., Slezak P., Efendic S., et al. Can somatostatin prevent injection pancreatitis after ERCP?. Hepatogastroenterology 39 (1992) 259-261
30. Poon R.T., Yeung C., Lo C.M., et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized, controlled trial. Gastrointest Endosc 49 (1999) 660-662
31. Cavallini G., Tittobello A., Frulloni L., et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 335 (1996) 919-923
32. Hajiro K., Tsujimura D., Inoue R., et al. Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography. Gendai Iryo 10 (1978) 1375-1379
33. Kuno N., Kasugai T., Oguri T., et al. Study on prevention of complication associated with endoscopic retrograde cholangiopancreatography (ERCP): a controlled trial of a new protease inhibitor, FOY, in hyperamylasemia following endoscopic retrograde cholangiopancreatography. Gendai Iryo 10 (1978) 571-575
34. Shimizu Y., Takahashi H., Deura M., et al. Prophylactic effects of preoperative administration of gabexate mesylate (FOY) on post-ERCP pancreatitis. Gendai Iryo 11 (1979) 540-544
35. Salamon V., Kuntz H.D., and May B. Wirkung des synthetischen proteinase-inhibitors FOY auf die hyperamylasamie nach ERP. In: Grozinger K.H., Schrey A., and Wabnitz R.W. (Eds). Proteinasen-Inhibition, FOY Workshop, 1981, Dusseldorf, Germany (1982), Wolf G & Sohn, Munchen, Germany 132-135
36. Benini L., Angelici G., Lavorini E., et al. Effect of a new enzyme inhibitor (gabexate mesylate-FOY) on hyperenzymemia induced by ERCP: a double blind study. [abstract]. Digestion 32 (1985) a165
37. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
38. Dersimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-178
39. Klein S., Simes J., and Blackburn G.L. Total parenteral nutrition and cancer clinical trial. Cancer 58 (1986) 1378-1386
40. Leandro G. Meta-analysis in medical research (2004), Blackwell, Oxford
41. Colditz G.A., Miller G.N., and Mosteller F. How study design affects outcomes in comparisons of therapy. Stat Med 8 (1989) 441-466
42. Kjaergard L.J., Villumsen J., and Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135 (2001) 982-989
43. Freeman M.L. Adverse outcomes of ERCP. Gastrointest Endosc 56 Suppl (2002) S273-S282